Day One Biopharmaceuticals preliminary FY24 OJEMDA product revenue $57.2M

Day One Biopharmaceuticals (DAWN) announced its preliminary unaudited 2024 OJEMDA net product revenue, cash and investments at year-end and delivered business updates. First dose cohort cleared in Phase 1a/b clinical trial of DAY301; Ended 2024 with approximately $531.7 million in cash, cash equivalents and short-term investments. 2025 Upcoming Priorities and Milestones: Continue to grow OJEMDA revenue in relapsed or refractory pLGG.; Advance the existing pipeline, including the FIREFLY-2 Phase 3 clinical trial with tovorafenib in the front-line setting, and DAY301 in the Phase 1a/b trial; Pursue business development opportunities to expand the pipeline.; Maintain a self-sustaining financial position for investing in durable growth.